Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00389948|
Recruitment Status : Completed
First Posted : October 19, 2006
Last Update Posted : April 16, 2007
|Condition or disease||Intervention/treatment||Phase|
|Heartburn||Drug: Lanzoprazole||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||576 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of 14 Day Treatment With Lansoprazole 15 mg Once a Day in Frequent Heartburn|
|Study Start Date :||June 2006|
|Study Completion Date :||January 2007|
- To demonstrate that repeated daily doses of 15 mg of lansoprazole are effective in increasing the proportion of days with no heartburn during study treatment, when compared to placebo.
- To determine the proportion of nighttimes with no heartburn during 14 days of treatment in subjects receiving lansoprazole versus placebo
- To determine the proportion of subjects with no heartburn during day 1 in those receiving lansoprazole versus placebo
- Evaluation of lansoprazole safety.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00389948
Show 28 Study Locations